McCarthy Asset Management’s Filana Therapeutics FLNA Stock Holding History

McCarthy Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-68	Closed	-$3K	–	237
2022 Q1	$3K	Hold	68	–	–	﹤0.01%	250
2021 Q4	$3K	Buy	68 +8	+13%	+$420	﹤0.01%	248
2021 Q3	$4K	Sell	60 -25	-29%	-$2.09K	﹤0.01%	222
2021 Q2	$7K	Sell	85 -15	-15%	-$804	0.01%	225
2021 Q1	$4K	Buy	+100	New	+$3.93K	﹤0.01%	234

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

McCarthy Asset Management's FLNA Position: Q2 2022 in Review

McCarthy Asset Management sold out of Filana Therapeutics (FLNA) in Q2 2022, closing a stake of 68 shares — an estimated $3K sold.

McCarthy Asset Management first reported a position in FLNA in Q1 2021 and held it in 5 quarters. The position peaked at $7K in Q2 2021. 149 funds tracked by Wall St. Rank hold FLNA as of Q2 2022.

McCarthy Asset Management reported no remaining Filana Therapeutics position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 68 Filana Therapeutics shares in Q2 2022, an estimated $3K.
McCarthy Asset Management first reported a position in Filana Therapeutics in Q1 2021 and held it in 5 quarters.
McCarthy Asset Management's Filana Therapeutics position peaked at $7K in Q2 2021.
149 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.